Efficacy of Tofacitinib for the Treatment of Psoriatic Arthritis: Pooled Analysis of Two Phase 3 Studies

ConclusionsIn a pooled analysis of csDMARD-IR/TNFi-na ïve and TNFi-IR patients, tofacitinib was superior to placebo at month 3 across four PsA domains: peripheral arthritis, psoriasis, enthesitis and dactylitis.Trial RegistrationOPAL Broaden (NCT01877668); OPAL Beyond (NCT01882439).FundingPfizer Inc.

http://link.springer.com/10.1007/s40744-018-0131-5

Source: Rheumatology and Therapy - November 9, 2018 Category: Rheumatology Source Type: research